| Name | Title | Contact Details |
|---|---|---|
Hamid Bafghi |
Profile |
Brown & Brown is a prominent insurance brokerage firm based in Daytona Beach, Florida, with a history that dates back to 1939. Originally founded as Brown & Owen, the company has grown to become one of the largest insurance intermediaries globally and is publicly traded on the NYSE under the ticker BRO. It has been part of the S&P 500 since 2021 and has earned recognition as a Great Place to Work Certified™ company since 2018. The company operates through four main business segments: Business Insurance, which offers tailored risk management solutions; Personal Insurance, providing coverage for high-net-worth individuals; Programs & Underwriting, managing niche insurance programs; and Wholesale Brokerage, serving as an intermediary for agents and carriers. Brown & Brown emphasizes a customer-focused approach and has achieved significant growth through both organic expansion and strategic acquisitions. Its diverse service offerings cater to businesses, individuals, and insurance agents, reinforcing its position as a leader in the insurance industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Dare to bank boldly and dream big. Whatever your dreams, its time to take your financial future to new heights. Were committed to helping you get there. Embold Credit Union is a local, member-owned, not-for-profit financial cooperative. That means when you join Embold, you become a member and an owner. All decisions we make keep your best interests at the forefront.
Luxury mattresses, bed frames, sheets & pillows. 101-Night Mattress Sleep Trial. Free shipping, hassle-free returns & easy online shopping.